Streetbeat News

Partnerships

PFE

VALN

Valneva and Pfizer have released Phase 2 booster findings for their Lyme disease vaccine candidate in pediatric and adolescent populations. The results show promising efficacy and safety profiles.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 6:39 am

MDTKF

TSM

MediaTek has successfully developed its first chip using Taiwan Semiconductor Manufacturing Company's (TSMC) advanced 3nm technology. The company plans to start mass production of the chip in 2024.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 5:29 am

NVDA

TSLA

Tesla CEO Elon Musk has reiterated the difficulty of managing data from its fleet of vehicles, stating that the company uses less than 1% of all videos for training its full self-driving (FSD) software. Tesla has access to about 160 billion frames of video from its cars every day. The company will use both NVIDIA and its own custom-built Dojo supercomputer to process the large amount of data from Tesla’s growing fleet of vehicles and train its FSD software.

Portfolio Pulse from Anan Ashraf

September 07, 2023 | 4:52 am

AAPL

GOOG

YouTube TV, owned by Alphabet Inc., is set to launch its NFL 'Sunday Ticket' streaming service this weekend. The service, which was previously hosted by DirecTV, is part of a seven-year contract worth over $2 billion per season. The package will be available as an add-on on YouTube TV or separately on YouTube Primetime Channels. Last year, YouTube outbid several companies, including Apple Inc., for the rights to NFL Sunday Ticket.

Portfolio Pulse from Benzinga Neuro

September 07, 2023 | 4:16 am

MSFT

OpenAI, backed by Microsoft Corporation (NASDAQ:MSFT), is preparing for its first developer conference, OpenAI DevDay, on November 6. CEO Sam Altman has clarified that there will be no major AI model releases like GPT-5 or 4.5 at the event. The conference will feature updates on Global Illumination, an AI design studio acquired by OpenAI, and possibly on the availability of GPT-4's image understanding capabilities. OpenAI, which currently generates over $80 million in monthly revenue, aims to generate more than $1 billion in revenue by selling AI software and computing capacity within the next year.

Portfolio Pulse from Ananya Gairola

September 07, 2023 | 3:39 am

PSFE

Paysafe Ltd. (NYSE:PSFE) and Eightcap are advancing their partnership with the introduction of an Embedded Trading Wallet solution for partners and merchants in the EU, scheduled for late 2023. The solution will bring together compliance expertise and payments and trading capabilities. This follows a 2016 partnership where Paysafe provided various payment options for Eightcap global traders. Paysafe's Q2 earnings showed a 6% Y/Y total revenue growth, with digital wallet use revenue increasing by 5%.

Portfolio Pulse from Khyathi Dalal

September 06, 2023 | 10:59 pm

ARKK

ETHUSD

Ark Invest, in collaboration with 21Shares, has submitted a proposal to the SEC for an Ethereum-based ETF named ARK 21Shares Ethereum ETF. The ETF aims to offer investors direct access to Ethereum and will be listed on the Cboe BZX Exchange. The SEC's approval for this ETF is still pending.

Portfolio Pulse from Murtuza Merchant

September 06, 2023 | 10:25 pm

CMND

Clearmind Medicine (NASDAQ:CMND) has partnered with Johns Hopkins University School of Medicine to conduct a Phase I/IIa clinical trial on its proprietary MEAI-based compound CMND-100 for the potential treatment of Alcohol Use Disorder. The clinical program will involve a multinational, multi-center study in both healthy volunteers and people with AUD. This is the second US clinical site to join the trial, following Yale School of Medicine’s Department of Psychiatry.

Portfolio Pulse from Lara Goldstein

September 06, 2023 | 9:36 pm

PHRRF

PharmaTher Holdings (OTCQB:PHRRF) has submitted a priority-original Abbreviated New Drug Application (ANDA) for its proprietary racemic ketamine, KETARX, to the FDA. The company expects an expedited review and anticipates KETARX’s approval and commercial launch in the U.S. in Q2 2024. PharmaTher is also working on international approvals to meet the growing global demand for ketamine. The company is partnering with Vitruvias Therapeutics to commercialize KETARX in the U.S.

Portfolio Pulse from Lara Goldstein

September 06, 2023 | 9:21 pm

AI

C3 AI has launched the C3 Generative AI Suite, which includes 28 new domain-specific generative AI offerings. The suite combines C3 AI's enterprise domain and industry expertise with the latest innovations in generative AI. The offerings have been well received by the market with projects now in place at Georgia-Pacific, Flint Hills Resources, Nucor, Pantaleon, Con Edison, the U.S. Missile Defense Agency, and a U.S. intelligence agency. The solutions can operate on the cloud platform of the customer's choice including Google Cloud Platform, AWS, and Microsoft Azure.

Portfolio Pulse from Happy Mohamed

September 06, 2023 | 8:39 pm